Peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α, encoded by PPARGC1) was identified as a potential therapeutic target for early intervention in PD patients with diabetes[45], [46], and glucagon-like peptide-1 (GLP-1) and its analogues could also be possible treatments for cognitive deficits in individuals with neurodegenerative disorders [47], [48]. This evidence concerns the gene PPARGC1A and Cognitive impairment.